

***Bcr – Abl Mutations in Chronic Myeloid  
Leukemia***

***M.Sc. Thesis***

*Submitted for fulfillment of M.Sc. Degree in Internal Medicine*

Presented by

***Amr Reda Ahmed El Bahy***

M.B., B.Ch.

Under supervision of

***Prof. Dr. Mervat Mohamed Mattar***

Professor of Internal Medicine  
Faculty of Medicine, Cairo University

***Dr. Heba Sayed Assal***

Assistant Professor of Internal Medicine  
National Research Centre

***Dr. Ghada Ibrahim Mossallam***

Fellow of Clinical Pathology  
National Cancer Institute  
Cairo University

Faculty of Medicine  
Cairo University  
2008

**`The longer you can look back -  
the further you can look forward'**

Winston Churchill  
Addressing the Royal College of Physicians,  
London 1944.

At the time that Churchill was speaking in 1944, leukemia was a fatal disease that had been identified 100 years before. The disease was described as the dreaded leukemias, sinister and poorly understood.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ رَبِّ اشْرَحْ لِي صَدْرِي # وَيَسِّرْ لِي أَمْرِي

# وَأَحِلْ لِي غُضُوفاً مِّنْ لِّسَانِي # يَفْقَهُوا قَوْلِي

صدق الله العظيم

سورة طه (٢٥ : ٢٨)

## Acknowledgement

First of all, I would like to thank **God**, for providing me with the strength and persistence to finish this work.

I would like to express my greatest thanks for *Prof Dr Mervat Mattar*, Professor of Internal Medicine and Clinical Hematology, Cairo University for her continuous support and back-up. With her guidance, I was able to find for myself a place in the field of Hematology.

I am extremely grateful for *Dr Ghada Mossallam*, Fellow of Clinical Pathology, National Cancer Institute who adopted the idea from the first place, and offered her time and effort in order to have this work see the light.

I would like to express my thanks to *Dr Moh Abdel Mooty Abou Samra*, Lecturer of Medical Oncology, National Cancer Institute for helping me in collecting the samples and organizing the results.

I would like to also thank the *Internal Medicine & Community Medicine* Departments at the *National Research Centre* for their support.

Last but not least, I am much grateful for all patients who shared in clinical trials and in the fight against malignant diseases. The fight still continues ...

To all of them, I am greatly indebted ...

Amr

*This Work is dedicated*

*To...*

*My Parents ...*

*My Brothers ...*

*And to everyone who helped me  
accomplish this work ...*

## Abstract

Chronic myeloid leukemia is one of the myeloproliferative disorders characterized by t(9;22)(q34;q11) known as Philadelphia chromosome. This leads to the formation of a fusion gene Bcr-Abl tyrosine kinase having properties necessary for malignant transformation. Imatinib is a leading tyrosine kinase inhibitor that showed marked cytogenetic responses, but sometimes out casted by presence of resistance. Resistance has been traced mainly to occurrence of mutations within Bcr-Abl domain making it insensitive to Imatinib. Our aim is to determine the presence of Bcr-Abl kinase domain mutations among chronic myeloid leukemia patients before and during therapy with Imatinib. 24 patients at different phases of the disease were recruited and mutation analysis was done using ASO-PCR for 3 mutations: T315I, M351T, and E255K. One patient with accelerated phase CML demonstrated presence of M351T mutation and switched to second generation tyrosine kinase inhibitor Nilotinib. Further large scale studies are recommended to detect presence of Bcr-Abl mutations and assess their frequency among Egyptian chronic myeloid leukemia.

### **Key words:**

- Bcr-Abl.
- Mutations.
- Imatinib.
- CML.

## *Table of Contents*

<i>Introduction</i>	1
<i>Aim of the Work</i>	3
<u><i>Review of Literature:</i></u>	
- <i>History of CML</i>	4
- <i>Classification</i>	7
- <i>Aetiology of CML</i>	8
- <i>Epidemiology</i>	10
- <i>Cytogenetic &amp; Molecular Biology</i>	11
- <i>Clinico-Pathological Features</i>	22
- <i>Phases of CML</i>	27
- <i>Prognostic Factors</i>	41
- <i>Monitoring CML patient</i>	42
- <i>Treatment Options</i>	45
- <i>BCR-ABL Tyrosine Kinase Inhibition</i>	58
- <i>Imatinib</i>	60
- <i>Imatinib Resistance</i>	68
- <i>Management of Imatinib resistance</i>	74
- <i>Monitoring treatment of CML</i>	81
<i>Patients &amp; Methods</i>	86
<i>Results</i>	90
<i>Discussion</i>	101
<i>Conclusion</i>	111
<i>Recommendations</i>	112
<i>Summary</i>	113
<i>References</i>	117
<i>Appendix</i>	132
<i>Arabic Summary</i>	

## List of Tables

<b>Table (1):</b>	The 2008 World Health Organization classification scheme for myeloid neoplasms	9
<b>Table (2):</b>	The different types of leukemia and the corresponding <i>BCR/ABL</i> breakpoints	19
<b>Table (3):</b>	An abbreviated summary of different classification schemes for CML	28
<b>Table (4):</b>	Secondary genetic and molecular abnormalities in CML-BC	33
<b>Table (5):</b>	Clinical course of untreated CML	34
<b>Table (6):</b>	Definitions of Response	44
<b>Table (7):</b>	Time based landmarks for evaluation of response	44
<b>Table (8):</b>	Adverse effects associated with Imatinib therapy	67
<b>Table (9):</b>	Molecular targets of available chronic myelogenous leukemia treatments and those currently being evaluated	80
<b>Table (10):</b>	Proposed approach to monitoring CML	85
<b>Table (11):</b>	Descriptive characteristics of the studied group	90
<b>Table (12):</b>	The Mean and Standard Deviation of age and different laboratory results among the patients at initial presentation	91

<b>Table (13):</b>	Patients receiving initial dosages of Imatinib therapy	92
<b>Table (14):</b>	Monitoring patients for HR at 3 months and for CgR at 6 months	93
<b>Table (15):</b>	Current Dosage and Other Drugs Patients receiving	94
<b>Table (16):</b>	Initial Cytogenetic results (Ph %), after 6 months of treatment and the prognosis of drugs after 6 months on cytogenetic results	95
<b>Table (17):</b>	Results of <i>BCR-ABL</i> level at the beginning of the study and after 6 months of treatment	95
<b>Table (18):</b>	Mutation <i>T315I</i> , <i>M351</i> and <i>E255K</i> results among the studied patients	96
<b>Table (19):</b>	Relation between Initial Dose of Imatinib and Cytogenetic response after 6 months of treatment	97
<b>Table (20):</b>	Mean and SD of Cytogenetic response (Ph %) after six months of treatment with different doses of Imatinib	97
<b>Table (21):</b>	Relation between the initial dose of treatment and current choice of treatment	98

<b>Table (22):</b>	Relation between Cytogenetic responses at 6 months with <i>BCR-ABL</i> level at 6 months of Imatinib therapy	98
<b>Table (23):</b>	Descriptive Data and Laboratory Results of <i>M351</i> Positive case	99

## List of Figures

<b>Figure (1):</b>	Metaphase picture showing the small abnormal Ph chromosome	6
<b>Figure (2):</b>	The translocation of t(9;22)(q34;q11) in CML	11
<b>Figure (3):</b>	Structure of <i>ABL</i> protein	13
<b>Figure (4):</b>	Structure of <i>BCR</i> protein	14
<b>Figure (5):</b>	Locations of the breakpoints in the <i>ABL</i> and <i>BCR</i> genes and structure of the chimeric <i>BCR/ABL</i> mRNA transcripts derived from the various breaks	15
<b>Figure (6):</b>	Functional domains of p210 <sup>BCR/ABL</sup>	17
<b>Figure (7):</b>	Signaling pathways of p210 <sup>BCR/ABL</sup>	19
<b>Figure (8):</b>	Patient with massive splenomegaly in chronic phase chronic myeloid leukemia	23
<b>Figure (9):</b>	CML. High-power view of the peripheral blood demonstrates neutrophils, bands, and a circulating myelocyte	25
<b>Figure (10):</b>	CML. High-power view of a hypercellular bone marrow biopsy with prominent granulocytic component	25
<b>Figure (11):</b>	CML. Karyotypic analysis demonstrating the abnormal Philadelphia chromosome (22) and the reciprocal abnormal chromosome 9 which results from the translocation	25

<b>Figure (12):</b>	CML. Fluorescence in situ hybridization (FISH) with red signal marking the <i>ABL</i> gene on a normal chromosome 9, green signal representing <i>BCR</i> on a normal chromosome 22, and a combined signal (yellow) demonstrating the <i>BCR/ABL</i> fusion on the Philadelphia chromosome	26
<b>Figure (13):</b>	Conceptual models of CML progression	29
<b>Figure (14):</b>	CML Progression	34
<b>Figure (15):</b>	Mode of Action of STI 571	59
<b>Figure (16):</b>	Imatinib Mesylate	60
<b>Figure (17):</b>	Mechanism of Action of <i>BCR-ABL</i> and of Its Inhibition by Imatinib	62
<b>Figure (18):</b>	Kaplan–Meier Estimates of the Cumulative Best Response to Initial Imatinib Therapy	64
<b>Figure (19):</b>	Ribbon representation of the structure of the Abl kinase domain in complex with STI-571	70
<b>Figure (20):</b>	Panel B, amino acid substitutions in the kinase domain of <i>BCR-ABL</i> that were detected in patients. P denotes P loop, C catalytic domain, and A activation loop	71
<b>Figure (21):</b>	The relative frequency of <i>BCR-ABL</i> kinase domain mutations detected at 31 different positions in clinical specimens	73
<b>Figure (22):</b>	Male and female percentage among the study group	91

<b>Figure (23):</b>	Mean Cytogenetic Metaphase % at the beginning of the study and after 6 months of Imatinib therapy	93
<b>Figure (24):</b>	Mean Quantitative <i>BCR-ABL</i> values at the beginning of the study and after 6 months of Imatinib therapy	94
<b>Figure (25):</b>	Lane 1: DNA molecular weight marker (50bp), Lanes 2, 4, 6 and 8 represent the PCR reaction using <i>T315I</i> wild-type primers of <i>M351T</i> +ve case respectively. Lanes 3, 5, 7 and 9 represent the PCR reaction using <i>T315I</i> mutated- type primers in the same patient respectively showing absence of mutation.	100
<b>Figure (26):</b>	Lane 1: MW marker (100bp), Lanes 2, 4 and 6 represent the PCR reaction using <i>M351T</i> wild-type primers of <i>M351T</i> +ve case respectively. Lanes 3, 5, and 7 represent the PCR reaction using <i>M351T</i> mutated type- primers showing presence of mutation	100

## **List of Abbreviations**

aCML	Atypical chronic myeloid leukemia
ALL	Acute lymphoblastic leukemia
Allo-SCT	Allogeneic stem cell transplantation
A-loop	Activation loop
AML	Acute myeloid leukemia
A-MuLV	Abelson murine leukemia virus
AP	Accelerated phase
ATP	Adenosine triphosphate
ATR	Ataxia telangiectasia related protein
BCR	Breakpoint cluster region
BCR-ABL	Break point cluster region - Abelson murine leukemia
BM	Bone marrow
BMT	Bone marrow transplant
BP	Blastic phase
CBL	Casitas B-lineage lymphoma
CCR	Complete cytogenetic response
CCyR	Complete cytogenetic response
CEL	Chronic eosinophilic leukemia
CG	Cytogenetic
CgR	Cytogenetic Response
CHR	Complete hematologic response
CML	Chronic myeloid leukemia
CMML	chronic myelomonocytic leukemia

CMPD	Chronic myeloproliferative disorders
C-myc	Cellular myelocytomatosis viral oncogene
CNL	Chronic neutrophilic leukemia
CR	Cytogenetic response
CP	Chronic phase
CYP 450	Cytochrome P450
DLI	Donor lymphocyte infusion
DNA	Deoxyribonucleic acid
ET	Essential thrombocythemia
FAK	Focal adhesion kinase
FDA	Food and Drug Administration
FISH	Fluorescent in-situ hybridization
FTI	Farnesyl transferase inhibitors
GIT	Gastro intestinal tract
GIST	Gastrointestinal stromal tumor
GM-CSF	Granulocyte Macrophage - Colony Stimulating Factor
GST	Glutathione S -Transferase
GTP	Guanosine triphosphate
GvHD	Graft versus host disease
GVL	Graft versus leukemia
HES	Hypereosinophilic syndrome
HHT	Homoharringtonine
HLA	Human leukocyte antigen
HOXA9	Homeobox gene A9